EDISON EQUITY RESEARCH - THRESHOLD PHARMACEUTICALS

EDISON EQUITY RESEARCH: THRESHOLD PHARMACEUTICALS - TARLOXOTINIB ADVANCES INTO TWO PHASE II TRIALS

Tarloxitinib (TH-4000), Threshold’s earlier-stage hypoxia asset, has now started two Phase II studies, as planned. With active development now ongoing we include an indicative valuation for this asset in our rNPV, which has increased to $1,023m ($14.3/share). Tarloxotinib broadens and diversifies Threshold’s pipeline beyond evofosfamide, where we continue to expect the number of events needed for analysis of the Phase III STS and pancreatic trials should be reached in H215, with data shortly after.

Threshold Pharmaceuticals is a US oncology company focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Phase III for STS and pancreatic cancer and earlier trials in multiple other cancers, and is partnered with Merck KGaA.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports